ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2682

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Regulates Transcriptional Activation of the T Cell Receptor CD3 Zeta Chain in Human T Cells

Vaishali Moulton1, Andrew R. Gillooly2 and George C. Tsokos3, 1Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: SLE and T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants

Session Type: Abstract Submissions (ACR)

Background/Purpose T cells from patients with systemic lupus erythematosus (SLE) express reduced amounts of the critical CD3 zeta signaling chain, and are poor producers of the vital cytokine interleukin (IL)-2.  Using oligonucleotide-pulldown and mass spectrometry approaches, we previously identified the serine arginine-rich splicing factor 1 (SRSF1) binding to the 3`UTR of CD3 zeta mRNA. We showed that SRSF1 regulates alternative splicing of the CD3 zeta 3`UTR to promote a full length 3`UTR over an unstable splice variant, and thus promotes expression of CD3 zeta chain. SLE T cells exhibit reduced expression of SRSF1, more so patients with worse disease as evidenced by higher SLE disease activity index (SLEDAI). SRSF1 and the serine arginine (SR) proteins have recently been suggested to regulate transcription, in addition to regulating post-transcriptional events in gene expression such as alternative splicing, mRNA stability and translation. CD3 zeta is regulated by the Ets transcription factor family member E-74-like factor (Elf)-1 via two Ets binding sites (EBS) within the CD3 zeta promoter. In this study, we asked whether SRSF1 could activate CD3 zeta transcription and if this involved the transcription factor Elf-1.

Methods T cells were isolated by negative selection from peripheral blood of healthy individuals, and patients with SLE. Primary T cells were transfected with an SRSF1 or empty expression plasmid by nucleofection. mRNA and protein expression were assessed by real time quantitative pcr and immunoblotting respectively. To measure transcriptional activity, CD3 zeta promoter-luciferase constructs were co-transfected with increasing amounts of SRSF1 into 293T cells or into primary T cells, and luciferase activity measured using the dual luciferase assay system. Reporter chromatin immunoprecipitation (R-ChIP) assays were used to assess recruitment of proteins to the CD3 zeta promoter-luciferase construct. Specific antibodies were used to immunoprecipitate SRSF1, HA (tag present in the SRSF1 plasmid), and Elf-1 proteins. Quantitative real time pcr was performed to assess enrichment, and normalized to values obtained from inputs.

Results We show that SRSF1 expression directly correlates with CD3 zeta chain expression in T cells from patients with SLE. Overexpression and silencing of SRSF1 in primary T cells results in corresponding increase and decrease in total CD3 zeta mRNA expression. SRSF1 increases activity of the CD3 zeta promoter-luciferase in a dose dependent manner. SRSF1 overexpression leads to increased Elf-1 expression in T cells. Recruitment of SRSF1 and Elf-1 (a known transcriptional activator of CD3 zeta) to the CD3 zeta promoter is observed in T cells that overexpress SRSF1 compared to control transfected cells. 

Conclusion Our results reveal a novel transcriptional mechanism by which SRSF1 regulates CD3 zeta and may represent a molecular mechanism that contributes to the reduced CD3 zeta expression in SLE.


Disclosure:

V. Moulton,
None;

A. R. Gillooly,
None;

G. C. Tsokos,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serine-arginine-rich-splicing-factor-1-srsf1-regulates-transcriptional-activation-of-the-t-cell-receptor-cd3-zeta-chain-in-human-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology